ZA200501837B - Inhibitors of fatty aced amide hydrolase - Google Patents
Inhibitors of fatty aced amide hydrolase Download PDFInfo
- Publication number
- ZA200501837B ZA200501837B ZA200501837A ZA200501837A ZA200501837B ZA 200501837 B ZA200501837 B ZA 200501837B ZA 200501837 A ZA200501837 A ZA 200501837A ZA 200501837 A ZA200501837 A ZA 200501837A ZA 200501837 B ZA200501837 B ZA 200501837B
- Authority
- ZA
- South Africa
- Prior art keywords
- subunit
- group
- mmol
- fatty acid
- acid amide
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 48
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims abstract description 64
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims abstract description 60
- 125000003118 aryl group Chemical group 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 42
- 230000005764 inhibitory process Effects 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 229910052757 nitrogen Chemical group 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 14
- -1 chloro, hydroxyl Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 150000002431 hydrogen Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 claims 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- ZQESQBVNDBLWAM-WMZHIEFXSA-N n-[(3s,4r)-1-[2-(4-isothiocyanatophenyl)ethyl]-3-methylpiperidin-4-yl]-n-phenylpropanamide Chemical compound C([C@H]([C@H](C1)C)N(C(=O)CC)C=2C=CC=CC=2)CN1CCC1=CC=C(N=C=S)C=C1 ZQESQBVNDBLWAM-WMZHIEFXSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000002860 competitive effect Effects 0.000 abstract description 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 9
- 150000002916 oxazoles Chemical class 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 3
- 150000004866 oxadiazoles Chemical class 0.000 abstract description 3
- 150000004867 thiadiazoles Chemical class 0.000 abstract description 3
- 150000003557 thiazoles Chemical class 0.000 abstract description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 84
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 79
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 238000004440 column chromatography Methods 0.000 description 28
- 239000000843 powder Substances 0.000 description 28
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 27
- 239000000463 material Substances 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 26
- 229920006395 saturated elastomer Polymers 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 21
- LUMKXMDGONYZHO-UHFFFAOYSA-N 5-pyridin-2-yl-1,3-oxazole Chemical compound O1C=NC=C1C1=CC=CC=N1 LUMKXMDGONYZHO-UHFFFAOYSA-N 0.000 description 20
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 238000003818 flash chromatography Methods 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 15
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 15
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000011734 sodium Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- REOYOKXLUFHOBV-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidin-1-ylpyrazole-3-carboxamide;hydron;chloride Chemical compound Cl.CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 REOYOKXLUFHOBV-UHFFFAOYSA-N 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 244000309464 bull Species 0.000 description 7
- ROAHUIFQLRHKEY-UHFFFAOYSA-N 5-(1,3-thiazol-2-yl)-1,3-oxazole Chemical compound C1=CSC(C=2OC=NC=2)=N1 ROAHUIFQLRHKEY-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MLQBTMWHIOYKKC-KTKRTIGZSA-N (z)-octadec-9-enoyl chloride Chemical compound CCCCCCCC\C=C/CCCCCCCC(Cl)=O MLQBTMWHIOYKKC-KTKRTIGZSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 125000005313 fatty acid group Chemical group 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DOZFAFYEXMLJRD-UHFFFAOYSA-N 1-(4-pyridin-2-yl-1,3-oxazol-2-yl)octadec-9-en-1-one Chemical compound O1C(C(=O)CCCCCCCC=CCCCCCCCC)=NC(C=2N=CC=CC=2)=C1 DOZFAFYEXMLJRD-UHFFFAOYSA-N 0.000 description 3
- XWRIDDGXCXSSNJ-UHFFFAOYSA-N 1-(4-pyridin-4-yl-1,3-oxazol-2-yl)octadec-9-en-1-one Chemical compound O1C(C(=O)CCCCCCCC=CCCCCCCCC)=NC(C=2C=CN=CC=2)=C1 XWRIDDGXCXSSNJ-UHFFFAOYSA-N 0.000 description 3
- GGPJDZCXDVTNQT-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)butan-1-one Chemical compound O1C(C(=O)CCC)=NC=C1C1=CC=CC=N1 GGPJDZCXDVTNQT-UHFFFAOYSA-N 0.000 description 3
- FPPLZHMASKIGTJ-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)decan-1-one Chemical compound O1C(C(=O)CCCCCCCCC)=NC=C1C1=CC=CC=N1 FPPLZHMASKIGTJ-UHFFFAOYSA-N 0.000 description 3
- UZVWXZPPYMTLQE-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one Chemical compound O1C(C(=O)CCCCCC)=NC=C1C1=CC=CC=N1 UZVWXZPPYMTLQE-UHFFFAOYSA-N 0.000 description 3
- PCWWRGIJFHIOHI-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)hexadecan-1-one Chemical compound O1C(C(=O)CCCCCCCCCCCCCCC)=NC=C1C1=CC=CC=N1 PCWWRGIJFHIOHI-UHFFFAOYSA-N 0.000 description 3
- IADPDKBSCXXBSP-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)hexan-1-one Chemical compound O1C(C(=O)CCCCC)=NC=C1C1=CC=CC=N1 IADPDKBSCXXBSP-UHFFFAOYSA-N 0.000 description 3
- FSLIASFBWRGZPB-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)octadecan-1-one Chemical compound O1C(C(=O)CCCCCCCCCCCCCCCCC)=NC=C1C1=CC=CC=N1 FSLIASFBWRGZPB-UHFFFAOYSA-N 0.000 description 3
- VLJKBQYNIDBQEJ-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)octan-1-one Chemical compound O1C(C(=O)CCCCCCC)=NC=C1C1=CC=CC=N1 VLJKBQYNIDBQEJ-UHFFFAOYSA-N 0.000 description 3
- ZGJFSRIJAXSNIH-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)pentan-1-one Chemical compound O1C(C(=O)CCCC)=NC=C1C1=CC=CC=N1 ZGJFSRIJAXSNIH-UHFFFAOYSA-N 0.000 description 3
- NITIZFVXASLZNL-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)propan-1-one Chemical compound O1C(C(=O)CC)=NC=C1C1=CC=CC=N1 NITIZFVXASLZNL-UHFFFAOYSA-N 0.000 description 3
- CZDQFSCARAYQAZ-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)tetradecan-1-one Chemical compound O1C(C(=O)CCCCCCCCCCCCC)=NC=C1C1=CC=CC=N1 CZDQFSCARAYQAZ-UHFFFAOYSA-N 0.000 description 3
- YVORRVFKHZLJGZ-UHFFFAOYSA-N 4,5-Dimethyloxazole Chemical compound CC=1N=COC=1C YVORRVFKHZLJGZ-UHFFFAOYSA-N 0.000 description 3
- ODKHOKLXMBWVOQ-UHFFFAOYSA-N 4,5-diphenyl-1,3-oxazole Chemical compound O1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ODKHOKLXMBWVOQ-UHFFFAOYSA-N 0.000 description 3
- RDVIQCGECBBHNA-UHFFFAOYSA-N 5-(1-methylimidazol-2-yl)-1,3-oxazole Chemical compound CN1C=CN=C1C1=CN=CO1 RDVIQCGECBBHNA-UHFFFAOYSA-N 0.000 description 3
- ABYBUOHSJCFYNC-UHFFFAOYSA-N 5-(furan-3-yl)-1,3-oxazole Chemical compound O1C=CC(C=2OC=NC=2)=C1 ABYBUOHSJCFYNC-UHFFFAOYSA-N 0.000 description 3
- ICIMMICEDXGNOA-UHFFFAOYSA-N 5-thiophen-3-yl-1,3-oxazole Chemical compound S1C=CC(C=2OC=NC=2)=C1 ICIMMICEDXGNOA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- JPZIIIRVMJASPM-UHFFFAOYSA-N 1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one Chemical compound CCCCCCCCC=CCCCCCCCC(=O)C1=NN=CO1 JPZIIIRVMJASPM-UHFFFAOYSA-N 0.000 description 2
- OGPJTMSGDUTXCW-UHFFFAOYSA-N 1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one Chemical compound CCCCCCCCC=CCCCCCCCC(=O)C1=NN=CS1 OGPJTMSGDUTXCW-UHFFFAOYSA-N 0.000 description 2
- VESZWTBYTDWAEO-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)dodecan-1-one Chemical compound O1C(C(=O)CCCCCCCCCCC)=NC=C1C1=CC=CC=N1 VESZWTBYTDWAEO-UHFFFAOYSA-N 0.000 description 2
- RYEVVZKCCJNESX-UHFFFAOYSA-N 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)nonan-1-one Chemical compound O1C(C(=O)CCCCCCCC)=NC=C1C1=CC=CC=N1 RYEVVZKCCJNESX-UHFFFAOYSA-N 0.000 description 2
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- KHAVLLBUVKBTBG-UHFFFAOYSA-N dec-9-enoic acid Chemical compound OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 2
- KHOZXYSECXUORA-UHFFFAOYSA-N dec-9-ynoic acid Chemical compound OC(=O)CCCCCCCC#C KHOZXYSECXUORA-UHFFFAOYSA-N 0.000 description 2
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- WEKFVWJGTAVCKQ-UHFFFAOYSA-N octadec-9-en-1-one Chemical compound CCCCCCCCC=CCCCCCCC[C]=O WEKFVWJGTAVCKQ-UHFFFAOYSA-N 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- RGTIBVZDHOMOKC-UHFFFAOYSA-N stearolic acid Chemical compound CCCCCCCCC#CCCCCCCCC(O)=O RGTIBVZDHOMOKC-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OOXRAGYSSZWMAE-DOFZRALJSA-N (5z,8z,11z,14z)-icosa-5,8,11,14-tetraen-1-amine Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCN OOXRAGYSSZWMAE-DOFZRALJSA-N 0.000 description 1
- NOUXLRBJQCWNDM-QXMHVHEDSA-N (Z)-N-methoxynonadec-9-enamide Chemical compound CCCCCCCCC/C=C\CCCCCCCC(=O)NOC NOUXLRBJQCWNDM-QXMHVHEDSA-N 0.000 description 1
- ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 description 1
- ABJVJNOVNSCXRT-UHFFFAOYSA-N 1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-ol Chemical compound CCCCCCCCC=CCCCCCCCC(O)C1=NN=CO1 ABJVJNOVNSCXRT-UHFFFAOYSA-N 0.000 description 1
- QIBXDPZFAVJEAI-UHFFFAOYSA-N 1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-ol Chemical compound CCCCCCCCC=CCCCCCCCC(O)C1=NN=CS1 QIBXDPZFAVJEAI-UHFFFAOYSA-N 0.000 description 1
- JIVKXULXTMWQMJ-UHFFFAOYSA-N 1-(4-pyridin-3-yl-1,3-oxazol-2-yl)octadec-9-en-1-one Chemical compound O1C(C(=O)CCCCCCCC=CCCCCCCCC)=NC(C=2C=NC=CC=2)=C1 JIVKXULXTMWQMJ-UHFFFAOYSA-N 0.000 description 1
- UEBFLTZXUXZPJO-UHFFFAOYSA-N 1-methylimidazole-2-carbaldehyde Chemical compound CN1C=CN=C1C=O UEBFLTZXUXZPJO-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-QJRAZLAKSA-N 1-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)CO RZRNAYUHWVFMIP-QJRAZLAKSA-N 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- UNSAJINGUOTTRA-UHFFFAOYSA-N 3-(3-bromophenyl)prop-2-yn-1-ol Chemical compound OCC#CC1=CC=CC(Br)=C1 UNSAJINGUOTTRA-UHFFFAOYSA-N 0.000 description 1
- MHROLVDNBHVTMB-DOFZRALJSA-N 3-[(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoxy]propane-1,2-diol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCOCC(O)CO MHROLVDNBHVTMB-DOFZRALJSA-N 0.000 description 1
- OIMRLHCSLQUXLL-UHFFFAOYSA-N 3-chlorobutan-2-one Chemical compound CC(Cl)C(C)=O OIMRLHCSLQUXLL-UHFFFAOYSA-N 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VCTKYTBWZTZPHF-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-2-phenyl-1,3-oxazole Chemical compound ClCC1=C(C)OC(C=2C=CC=CC=2)=N1 VCTKYTBWZTZPHF-UHFFFAOYSA-N 0.000 description 1
- NTFMLYSGIKHECT-UHFFFAOYSA-N 4-phenyl-1,3-oxazole Chemical compound O1C=NC(C=2C=CC=CC=2)=C1 NTFMLYSGIKHECT-UHFFFAOYSA-N 0.000 description 1
- LVFOUJIXFNOKNR-UHFFFAOYSA-N 4-pyridin-2-yl-1,3-oxazole Chemical compound O1C=NC(C=2N=CC=CC=2)=C1 LVFOUJIXFNOKNR-UHFFFAOYSA-N 0.000 description 1
- WAKACMCPCVZHPZ-UHFFFAOYSA-N 4-pyridin-3-yl-1,3-oxazole Chemical compound O1C=NC(C=2C=NC=CC=2)=C1 WAKACMCPCVZHPZ-UHFFFAOYSA-N 0.000 description 1
- AJFKBWMKSZUJEE-UHFFFAOYSA-N 4-pyridin-4-yl-1,3-oxazole Chemical compound O1C=NC(C=2C=CN=CC=2)=C1 AJFKBWMKSZUJEE-UHFFFAOYSA-N 0.000 description 1
- AUWJUNNNFCQUHF-UHFFFAOYSA-N 5-(1-methylpyrrol-2-yl)-1,3-oxazole Chemical compound CN1C=CC=C1C1=CN=CO1 AUWJUNNNFCQUHF-UHFFFAOYSA-N 0.000 description 1
- LYPXTVWBKURKQH-UHFFFAOYSA-N 5-(furan-2-yl)-1,3-oxazole Chemical compound C1=COC(C=2OC=NC=2)=C1 LYPXTVWBKURKQH-UHFFFAOYSA-N 0.000 description 1
- YPYPBEGIASEWKA-UHFFFAOYSA-N 5-phenyl-1,3-oxazole Chemical compound O1C=NC=C1C1=CC=CC=C1 YPYPBEGIASEWKA-UHFFFAOYSA-N 0.000 description 1
- BYHDDXPKOZIZRV-UHFFFAOYSA-N 5-phenylpentanoic acid Chemical compound OC(=O)CCCCC1=CC=CC=C1 BYHDDXPKOZIZRV-UHFFFAOYSA-N 0.000 description 1
- OSPHPLUEQZNLHO-UHFFFAOYSA-N 5-pyridin-3-yl-1,3-oxazole Chemical compound O1C=NC=C1C1=CC=CN=C1 OSPHPLUEQZNLHO-UHFFFAOYSA-N 0.000 description 1
- AFQAOCIKCVFASO-UHFFFAOYSA-N 5-pyridin-4-yl-1,3-oxazole Chemical compound O1C=NC=C1C1=CC=NC=C1 AFQAOCIKCVFASO-UHFFFAOYSA-N 0.000 description 1
- VGBKCFRTMPSJLX-UHFFFAOYSA-N 5-thiophen-2-yl-1,3-oxazole Chemical compound C1=CSC(C=2OC=NC=2)=C1 VGBKCFRTMPSJLX-UHFFFAOYSA-N 0.000 description 1
- UDBYMCCQYQOBML-UHFFFAOYSA-N 6-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)hexan-1-one Chemical compound N=1C=C(C=2N=CC=CC=2)OC=1C(=O)CCCCCC1=CC=CC=C1 UDBYMCCQYQOBML-UHFFFAOYSA-N 0.000 description 1
- JTXZPQIXIXYMDY-UHFFFAOYSA-N 6-phenylhexanoic acid Chemical compound OC(=O)CCCCCC1=CC=CC=C1 JTXZPQIXIXYMDY-UHFFFAOYSA-N 0.000 description 1
- URWLWLXGACJYCO-UHFFFAOYSA-N 9-phenylnonanoic acid Chemical compound OC(=O)CCCCCCCCC1=CC=CC=C1 URWLWLXGACJYCO-UHFFFAOYSA-N 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- OFIDNKMQBYGNIW-UHFFFAOYSA-N arachidonic acid methyl ester Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC OFIDNKMQBYGNIW-UHFFFAOYSA-N 0.000 description 1
- 125000004097 arachidonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 description 1
- 230000003804 effect on potassium Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- UCVODTZQZHMTPN-UHFFFAOYSA-N heptanoyl chloride Chemical compound CCCCCCC(Cl)=O UCVODTZQZHMTPN-UHFFFAOYSA-N 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- OFIDNKMQBYGNIW-ZKWNWVNESA-N methyl arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC OFIDNKMQBYGNIW-ZKWNWVNESA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- PJMKKSGLJJBQMY-UHFFFAOYSA-N nonan-1-one Chemical compound CCCCCCCC[C]=O PJMKKSGLJJBQMY-UHFFFAOYSA-N 0.000 description 1
- NTQYXUJLILNTFH-UHFFFAOYSA-N nonanoyl chloride Chemical compound CCCCCCCCC(Cl)=O NTQYXUJLILNTFH-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 1
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadecene Natural products CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 description 1
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical compound C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- NRWMBHYHFFGEEC-UHFFFAOYSA-N selachyl alcohol Natural products CCCCCCCCC=CCCCCCCCCOCC(O)CO NRWMBHYHFFGEEC-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41724702P | 2002-10-08 | 2002-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200501837B true ZA200501837B (en) | 2006-06-28 |
Family
ID=32093990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200501837A ZA200501837B (en) | 2002-10-08 | 2005-03-03 | Inhibitors of fatty aced amide hydrolase |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7662971B2 (ru) |
| EP (2) | EP2093220A3 (ru) |
| JP (1) | JP4628789B2 (ru) |
| KR (1) | KR20050070041A (ru) |
| CN (1) | CN1703407A (ru) |
| AT (1) | ATE431342T1 (ru) |
| AU (1) | AU2003275493A1 (ru) |
| BR (1) | BR0314980A (ru) |
| CA (1) | CA2501575A1 (ru) |
| DE (1) | DE60327640D1 (ru) |
| EA (1) | EA008767B1 (ru) |
| ES (1) | ES2325686T3 (ru) |
| MX (1) | MXPA05003762A (ru) |
| WO (1) | WO2004033652A2 (ru) |
| ZA (1) | ZA200501837B (ru) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| BR0314980A (pt) | 2002-10-08 | 2005-08-09 | Scripps Research Inst | Inibidores de hidrolase de amida de ácido graxo |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| DE102004039326A1 (de) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Neue medizinische Verwendungen und Verfahren |
| US7351724B2 (en) | 2004-10-15 | 2008-04-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| US7598249B2 (en) | 2004-12-30 | 2009-10-06 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| PE20070099A1 (es) | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| WO2007061862A2 (en) | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| CA2642737A1 (en) | 2006-02-17 | 2007-08-30 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
| WO2008013963A2 (en) * | 2006-07-28 | 2008-01-31 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| WO2008030532A2 (en) * | 2006-09-08 | 2008-03-13 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
| EP2152082B1 (en) * | 2007-05-25 | 2012-08-29 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| CA2689148A1 (en) * | 2007-05-31 | 2008-12-11 | The Scripps Research Institute | Tricyclic inhibitors of fatty acid amide hydrolase |
| EP2254415B1 (en) * | 2008-02-19 | 2013-01-23 | Janssen Pharmaceutica, N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| US20110184026A1 (en) * | 2008-06-19 | 2011-07-28 | Boger Dale L | C4-substituted alpha-keto oxazoles |
| WO2010005572A2 (en) * | 2008-07-09 | 2010-01-14 | The Scripps Research Institute | Alpha-keto heterocycles as faah inhibitors |
| AU2009279874B2 (en) * | 2008-08-04 | 2015-02-12 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of FAAH |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010068452A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| NZ593418A (en) * | 2008-12-24 | 2013-10-25 | Bial Portela & Ca Sa | Imidazole compounds for use as enzyme inhibitors |
| AR076687A1 (es) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| CN102656172B (zh) | 2009-09-09 | 2016-03-23 | 大日本住友制药株式会社 | 8-氧代二氢嘌呤衍生物 |
| NO2482815T3 (ru) * | 2009-10-02 | 2018-09-29 | ||
| WO2011060026A1 (en) | 2009-11-12 | 2011-05-19 | Jansen Pharmaceutica Nv | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| CN102858338A (zh) * | 2010-01-28 | 2013-01-02 | 默沙东公司 | 治疗疼痛及其它适应症的药物组合物 |
| KR101512548B1 (ko) | 2010-03-12 | 2015-04-15 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| US9669097B2 (en) * | 2010-09-20 | 2017-06-06 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| CN102964311B (zh) * | 2011-09-01 | 2016-03-09 | 大丰海嘉诺药业有限公司 | 一种合成4-甲基-5-烷氧基噁唑的方法 |
| ES2648188T3 (es) * | 2012-02-17 | 2017-12-29 | Epitech Group S.P.A. | Composiciones y métodos para la modulación de amidasas específicas para N-aciletanolaminas para ser usadas en la terapia de enfermedades inflamatorias |
| CN110128370A (zh) | 2013-01-29 | 2019-08-16 | 埃维克辛公司 | 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物 |
| NZ719916A (en) | 2013-11-01 | 2017-09-29 | Merial Inc | Antiparasitic and pesticidal isoxazoline compounds |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| WO2016160168A1 (en) * | 2015-02-20 | 2016-10-06 | Cytec Industries Inc. | Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions |
| JP2018513153A (ja) | 2015-04-24 | 2018-05-24 | オメロス コーポレーション | Ｐｄｅ１０インヒビターならびに関連する組成物および方法 |
| EP3095787A1 (en) * | 2015-05-22 | 2016-11-23 | Universiteit Leiden | Pharmaceutically active compounds as dag-lipase inhibitors |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA19269A1 (fr) * | 1980-09-16 | 1982-04-01 | Lilly Co Eli | Perfectionnement relatif a des derives de n-arylbenzamides . |
| US5665745A (en) * | 1994-10-24 | 1997-09-09 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| BR0314980A (pt) | 2002-10-08 | 2005-08-09 | Scripps Research Inst | Inibidores de hidrolase de amida de ácido graxo |
-
2003
- 2003-10-08 BR BR0314980-3A patent/BR0314980A/pt not_active IP Right Cessation
- 2003-10-08 EP EP09006391A patent/EP2093220A3/en not_active Withdrawn
- 2003-10-08 ES ES03759771T patent/ES2325686T3/es not_active Expired - Lifetime
- 2003-10-08 KR KR1020057006019A patent/KR20050070041A/ko not_active Application Discontinuation
- 2003-10-08 JP JP2004543576A patent/JP4628789B2/ja not_active Expired - Fee Related
- 2003-10-08 EA EA200500633A patent/EA008767B1/ru unknown
- 2003-10-08 WO PCT/US2003/031975 patent/WO2004033652A2/en active Application Filing
- 2003-10-08 EP EP03759771A patent/EP1549624B1/en not_active Expired - Lifetime
- 2003-10-08 CA CA002501575A patent/CA2501575A1/en not_active Abandoned
- 2003-10-08 US US10/528,552 patent/US7662971B2/en not_active Expired - Fee Related
- 2003-10-08 AT AT03759771T patent/ATE431342T1/de not_active IP Right Cessation
- 2003-10-08 CN CNA2003801009944A patent/CN1703407A/zh active Pending
- 2003-10-08 DE DE60327640T patent/DE60327640D1/de not_active Expired - Lifetime
- 2003-10-08 MX MXPA05003762A patent/MXPA05003762A/es not_active Application Discontinuation
- 2003-10-08 AU AU2003275493A patent/AU2003275493A1/en not_active Abandoned
-
2005
- 2005-03-03 ZA ZA200501837A patent/ZA200501837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003275493A1 (en) | 2004-05-04 |
| EP2093220A2 (en) | 2009-08-26 |
| ATE431342T1 (de) | 2009-05-15 |
| DE60327640D1 (ru) | 2009-06-25 |
| KR20050070041A (ko) | 2005-07-05 |
| EP1549624B1 (en) | 2009-05-13 |
| ES2325686T3 (es) | 2009-09-14 |
| EP1549624A2 (en) | 2005-07-06 |
| WO2004033652A3 (en) | 2004-09-16 |
| JP4628789B2 (ja) | 2011-02-09 |
| MXPA05003762A (es) | 2005-07-22 |
| JP2006502229A (ja) | 2006-01-19 |
| BR0314980A (pt) | 2005-08-09 |
| EA008767B1 (ru) | 2007-08-31 |
| US7662971B2 (en) | 2010-02-16 |
| EA200500633A1 (ru) | 2005-10-27 |
| US20060111359A1 (en) | 2006-05-25 |
| WO2004033652A2 (en) | 2004-04-22 |
| CA2501575A1 (en) | 2004-04-22 |
| CN1703407A (zh) | 2005-11-30 |
| EP1549624A4 (en) | 2006-09-20 |
| EP2093220A3 (en) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1549624B1 (en) | Inhibitors of fatty acid amide hydrolase | |
| JP4931893B2 (ja) | Ｐｐａｒ活性化化合物及びこれを含有する医薬組成物 | |
| Brown et al. | The chemistry of pseudomonic acid. 18. Heterocyclic replacement of the α, β-unsaturated ester: synthesis, molecular modeling, and antibacterial activity | |
| JP5301286B2 (ja) | Ｆｘ受容体を調節するための化合物及び方法 | |
| Wu et al. | Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors | |
| AU2007301607A1 (en) | Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | |
| JPWO2007119887A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| JP2006516254A (ja) | Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体 | |
| KR20010085340A (ko) | ｈＰＰＡＲγ 및 ｈＰＰＡＲα 활성제로서의 치환된옥사졸 및 티아졸 유도체 | |
| CA2322162A1 (en) | Inhibitors of phospholipase enzymes | |
| IE901360L (en) | 3- substituted-2-oxindole derivatives | |
| JP2012526783A (ja) | シクロペンタ［ｃ］ピロール−２−カルボン酸エステル誘導体、これらの調製およびこれらの治療用途 | |
| EP1581491A1 (en) | Indole derivatives as ppar modulators | |
| OA13359A (en) | 1,3-dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes. | |
| EP2262782A1 (en) | Novel aminomethyl benzene derivatives | |
| CA2696232A1 (en) | Protein tyrosine phosphatase 1b inhibitor, preparation methods and uses thereof | |
| JPWO2008016175A1 (ja) | ペルオキシソーム増殖剤活性化受容体の活性化剤 | |
| Thore et al. | Docking, synthesis, and pharmacological investigation of novel substituted thiazole derivatives as non-carboxylic, anti-inflammatory, and analgesic agents | |
| WO2015160772A1 (en) | Tetrahydro-benzoimidazolyl modulators of tgr5 | |
| ZA200304913B (en) | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient. | |
| Solomin et al. | Widely Exploited, Yet Unreported: Regiocontrolled Synthesis and the Suzuki–Miyaura Reactions of Bromooxazole Building Blocks | |
| JP2013538808A (ja) | Ｄｇａｔ１阻害剤としての複素環式化合物 | |
| Shibata et al. | Synthesis and Structure–Activity Relationships of Novel Zwitterionic Compounds as Peroxisome Proliferator Activated Receptor α/γ Dual Agonists with Improved Physicochemical Properties | |
| WO2016017699A1 (ja) | アゾールカルボン酸誘導体 | |
| Baashen | Synthesis of N, N'-diacylhydrazines and their use in various synthetic transformations |